Premium Phosphosite-Specific 7TM Antibodies
Your Resource for GPCR Research
Select Your Country of Delivery below

FP Receptor Antibodies

Close filters
No results were found for the filter!
NEW
Validation of the FP Prostanoid Receptor in transfected HEK293 cells
FP (non-phospho), FP Prostanoid Receptor Antibody
The non-phospho-FP Receptor Antibody is directed against the distal end of the carboxyl-terminal tail of human FP. It can be used to detect total FP receptors in Western blots independent of phosphorylation. The non-phospho-FP antibody...
$ 375.00 *
Details
NEW
Immunohistochemical identification of FP Prostanoid Receptor in pancreas
FP (IHC-grade), FP Prostanoid Receptor Antibody
The non-phospho-FP Receptor Antibody is directed against the distal end of the carboxyl-terminal tail of human FP. It can be used to detect total FP receptors in Western blots independent of phosphorylation. The non-phospho-FP antibody...
$ 375.00 *
Details

The FP receptor (Prostaglandin F receptor), encoded by the PTGFR gene, is a class A G protein–coupled receptor that primarily binds prostaglandin F2α (PGF2α). Pharmacologically, it is selectively activated by endogenous PGF2α as well as synthetic agonists such as Latanoprost, Travoprost, and Bimatoprost, which are widely used in the treatment of glaucoma. The FP receptor predominantly couples to Gq/11 proteins, leading to activation of phospholipase C, inositol trisphosphate (IP3) generation, intracellular calcium mobilization, and smooth muscle contraction. In ocular tissues, this signaling increases uveoscleral outflow of aqueous humor, thereby lowering intraocular pressure. The receptor is expressed in various tissues, including the uterus, corpus luteum, eye (particularly the ciliary body), and vascular smooth muscle, where it mediates reproductive, ocular, and vascular functions. In reproductive biology, FP signaling contributes to luteolysis and uterine contraction. Clinically, FP receptor agonists represent a major therapeutic class for open-angle glaucoma, and newer formulations aim to improve tolerability and sustained delivery. Ongoing research is also exploring selective FP modulators for reproductive and fibrotic disorders. For more information on prostanoid receptor pharmacology please refer to the IUPHAR database. For further reading refer to:

Coleman RA, Smith WL, Narumiya S. International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol Rev. 1994 Jun;46(2):205-29. PMID: 7938166.

Woodward DF, Jones RL, Narumiya S. International Union of Basic and Clinical Pharmacology. LXXXIII: classification of prostanoid receptors, updating 15 years of progress. Pharmacol Rev. 2011 Sep;63(3):471-538. doi: 10.1124/pr.110.003517. PMID: 21752876.

The FP receptor (Prostaglandin F receptor), encoded by the PTGFR gene, is a class A G protein–coupled receptor that primarily binds prostaglandin F2α (PGF2α). Pharmacologically, it... read more »
Close window
FP Receptor Antibodies

The FP receptor (Prostaglandin F receptor), encoded by the PTGFR gene, is a class A G protein–coupled receptor that primarily binds prostaglandin F2α (PGF2α). Pharmacologically, it is selectively activated by endogenous PGF2α as well as synthetic agonists such as Latanoprost, Travoprost, and Bimatoprost, which are widely used in the treatment of glaucoma. The FP receptor predominantly couples to Gq/11 proteins, leading to activation of phospholipase C, inositol trisphosphate (IP3) generation, intracellular calcium mobilization, and smooth muscle contraction. In ocular tissues, this signaling increases uveoscleral outflow of aqueous humor, thereby lowering intraocular pressure. The receptor is expressed in various tissues, including the uterus, corpus luteum, eye (particularly the ciliary body), and vascular smooth muscle, where it mediates reproductive, ocular, and vascular functions. In reproductive biology, FP signaling contributes to luteolysis and uterine contraction. Clinically, FP receptor agonists represent a major therapeutic class for open-angle glaucoma, and newer formulations aim to improve tolerability and sustained delivery. Ongoing research is also exploring selective FP modulators for reproductive and fibrotic disorders. For more information on prostanoid receptor pharmacology please refer to the IUPHAR database. For further reading refer to:

Coleman RA, Smith WL, Narumiya S. International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol Rev. 1994 Jun;46(2):205-29. PMID: 7938166.

Woodward DF, Jones RL, Narumiya S. International Union of Basic and Clinical Pharmacology. LXXXIII: classification of prostanoid receptors, updating 15 years of progress. Pharmacol Rev. 2011 Sep;63(3):471-538. doi: 10.1124/pr.110.003517. PMID: 21752876.

Recently viewed